Adherence to weight loss medications; post-marketing study from HMO pharmacy data of one million individuals

Diabetes Research and Clinical Practice

Volumn 94, Issue 2, 2011, Pages 269-275

  Hemo, Beatriz ^a   Endevelt, Ronit ^a,b   Porath, Avi ^a   Stampfer, Meir J ^c,d   Shai, Iris ^e  

^a MACCABI HEALTHCARE SERVICES   (Israel)

^b UNIVERSITY OF HAIFA   (Israel)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Adherence; Drugs; Weight loss

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; CARDIOVASCULAR AGENT; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ADULT; AGE; AGED; ARTICLE; BARIATRIC SURGERY; BODY MASS; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DEPRESSION; DIABETES MELLITUS; DRUG MARKETING; DRUG USE; FEMALE; HEART DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PATIENT COMPLIANCE; PHARMACY; POPULATION RESEARCH; SEX DIFFERENCE; WEIGHT REDUCTION;

ADULT; ANALYSIS OF VARIANCE; ANTI-OBESITY AGENTS; BODY MASS INDEX; COMORBIDITY; CYCLOBUTANES; DIABETES MELLITUS; FEMALE; HEALTH CARE SURVEYS; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; ISRAEL; LACTONES; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; OBESITY; ODDS RATIO; PRODUCT SURVEILLANCE, POSTMARKETING; REGISTRIES; TIME FACTORS; TREATMENT OUTCOME; WEIGHT LOSS; YOUNG ADULT;

EID: 81255192114     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2011.08.021     Document Type: Article

References (26)

1. Nathan D.M., Buse J.B., Davidson M.B., Ferrannini E., Holman R.R., Sherwin R., et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009, 52(1):17-30.
2. Wang Y., Beydoun M.A. The obesity epidemic in the United States - gender, age, socioeconomic, racial/ethnic, and geographic characteristics: a systematic review and meta-regression analysis. Epidemiol Rev 2007, 29:6-28.
3. World Health Organization Obesity: preventing and managing the global epidemic [WHO Technical report series No. 894] 2000, World Health Organization, Geneva.
4. Kuczmarski R.J., Flegal K.M., Campbell S.M., Johnson C.L. Increasing prevalence of overweight among US adults: the National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA 1994, 272:205-211.
5. Lexchin J., Bero L.A., Djulbegovic B., Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003, 326:1167-1170.
6. Rucker D., Padwal R., Li S.K., Curioni C., Lau D.C. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007, 335(7631):1194-1199.
7. Filippatos T.D., Derdemezis C.S., Gazi I.F., Nakou E.S., Mikhailidis D.P., Elisaf M.S. Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf 2008, 31(1):53-65.
8. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationfor%20PatientsandProviders/ucm191652.htm.
9. Padwal R.S., Majumdar S.R. Drug treatments for obesity: orlistat, sibutramine and rimonabant. Lancet 2007, 369:71-77.
10. Andrade S.E., Kahler K.H., Frech F., Chan K.A. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006, 15(August (8)):565-574. discussion 575-577.
11. National Institute for Health and Clinical Excellence. CG43 obesity: full guideline, section 1-introduction, methods and recommendations, ; 2006. http://guidance.nice.org.uk/CG43/guidance/section1/word/English.
12. Anderson C., Peterson C.B., Fletcher L., Mitchell J.E., Thuras P., Crow S.J. Weight loss and gender: an examination of physician attitudes. Obes Res 2001, 9(4):257-263.
13. Haynes R.B., Ackloo E., Sahota N., McDonald H.P., Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008, 16(April (2)):CD000011.
14. Wu J.R., Moser D.K., Lennie T.A., Burkhart P.V. Medication adherence in patients who have heart failure: a review of the literature. Nurs Clin North Am 2008, 43(1):133-153. vii-viii.
15. Gossec L., Tubach F., Dougados M., Ravaud P. Reporting of adherence to medication in recent randomized controlled trials of 6 chronic diseases: a systematic literature review. Am J Med Sci 2007, 334(4):248-254.
16. Stafford R.S., Radley D.C. National trends in antiobesity medication use. Arch Intern Med 2003, 163(9):1046-1050.
17. Padwal R., Kezouh A., Levine M., Etminan M. Long-term persistence with orlistat and sibutramine in a population-based cohort. Int J Obes (Lond) 2007, 31:1567-1570.
18. Srishanmuganathan J., Patel H., Car J., Majeed A. National trends in the use and costs of anti-obesity medications in England 1998-2005. J Public Health (Oxf) 2007, 29(2):199-202.
19. Padwal R.S. Trends in obesity and overweight-related office visits and drug prescriptions in Canada, 1998 to 2004. Obes Res 2005, 13(11):1905-1908.
20. Shai I., Schwarzfuchs D., Henkin Y., Shahar D.R., Witkow S., Greenberg I., et al. Weight loss with a low-carbohydrate Mediterranean, or low-fat diet. N Engl J Med 2008, 359(3):229-241.
21. Neff L.M., Aronne L.J. Pharmacotherapy for obesity. Curr Atheroscler Rep 2007, 9(6):454-462.
22. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - the evidence report: National Institutes of Health. Obes Res 1998, 6:51S-209S.
23. Stafford R.S., Farhat J.H., Misra B., Schoenfeld D.A. National patterns of physician activities related to obesity management. Arch Fam Med 2000, 9:631-638.
24. Amundsen M.O., Engdahl B., Berg C., Nordeng H. Cardiovascular comedication among users of antiobesity drugs: a population-based study. Pharm World Sci 2010, 32(6):752-758.
25. Padwal R., Kezouh A., Levine M., Etminan M. Long-term persistence with orlistat and sibutramine in a population-based cohort. Int J Obes (Lond) 2007, 31(10):1567-1570.
26. Ioannides-Demos L.L., Piccenna L., McNeil J.J. Pharmacotherapies for obesity: past, current, and future therapies. J Obes 2011, 2011:179674.